CD GENOMICS

Company Snapshot

Founded: 2004
Entity Type: Private
Region: U.S.
Headquarter: New York, U.S.
Key Geographics: U.S.
Corporate Address: SUITE 111, 17 Ramsey Road, Shirley, New York 11967, U.S. Tel. +1-631-338-8059 www.cd-genomics.com

Company Overview

CD Genomics delivers services to the research community for NGS, PacBio SMRT sequencing, Oxford Nanopore sequencing, and microarray analysis. The company has updated its platforms with advanced NGS, long-read sequencing, and microarray technology. To date, CD Genomics' senior bioinformaticians have processed more than 10,000 trace files and have acquired experience with high-end sequencing and microarray platforms such as Illumina HiSeq X, Illumina MiSeq, PacBio Sequel II, Oxford Nanopore MinION, Oxford Nanopore PromethION, MGI DNBSEQ-G400, MGI DNBSEQ-T7, Illumina iScan, and Sequenom MassArray iPLEX Gold.

CD GENOMICS In Reports

Global Microbiome Sequencing Market

According to our Research Report the microbiome sequencing market includes global revenue ($ Million) for base year data of 2023 and estimated data for the forecast period 2024 through 2029.

Global Next-Generation Sequencing on Drug Development Market

BCC Research Market Report says global next-generation sequencing market in drug development should reach $2.9 billion by 2028 from $1.3 billion in 2023 at a CAGR of 17.7%.

MicroRNA Research Tools, Diagnostics and Therapeutics: Global Markets

BCC Research Market Report says global artificial organs market should reach $17.7 billion by 2028 from $14.4 billion in 2023 at a compound annual growth rate of 4.2%.

Company's Business Segments

  • Product : Sequencing Platform, Gene Panels, Others
  • Service : Next Generation Sequencing, Long-Read Sequencing, Genotyping, Bioinformatics Services, Microarray Services

Applications/End User Industries

  • Agriculture
  • Food Science
  • Biotechnology
  • Oncology
  • Healthcare
  • Drug Development
AI Sentiment